News

Subcutaneous immunoglobulin is an effective and well-tolerated alternative to intravenous immunoglobulin for myasthenia gravis.

Eculizumab showed sustained activity and tolerability through 3 years for generalized myasthenia gravis.

The vice president of Medical Research at Biogen spoke about the intersection between high-quality data utilization and individualized medicine in multiple sclerosis.

The guidance provides clinicians with tools allowing for earlier and more accurate diagnosis of Alzheimer disease.

The professor of neurology at the University of Colorado posited that if certain criteria are met, it could be appropriate to take patients with multiple sclerosis off of DMT.

Data from multiple open-label extension trials have suggested that the therapy is more beneficial with earlier initiation compared to interferon ß-1a.

Over 10 million Americans suffer from debilitating chronic pain, according to new data that provides insights into the unrelenting problem of pain in America.

If approved, siponimod would be the first oral disease-modifying therapy with the potential to delay secondary progressive multiple sclerosis progression.

The postdoctoral scientist spoke about an actimetry-based method studying the clinical relevance of temporal dynamics of sleep to make the dynamics easily quantifiable in everyday context.

The medical director of digital health at Cleveland Clinic spoke about the role telehealth plays in a society where technology constantly advances and changes.

Brain injury and stroke studies have revealed that jealousy is indeed "in your head”-specifically in the left part of the cerebral cortex.

DESERVE is one of the first interventions potentially demonstrating the capacity to decrease racial and ethnic disparities in stroke risk reduction.

With a phase I trial of the therapy underway, EHP-101 is one step closer to potentially showing an effect on the pathology of multiple sclerosis.

The medical coordinator of the Multidisciplinary Sleep-Wake Disorders Center at Antwerp University Hospital spoke about how to address some of the issues faced in OSA treatment development.

The pediatric neurologist discussed the importance of the recent FDA approval of perampanel in pediatrics with partial-onset seizures with or without secondarily generalized seizures.

In a small trial, the AAVrh74.MHCK7.micro-dystrophin therapy has shown high levels of transduced micro-dystrophin expression.

Neurology News Network for the week of October 6, 2018.

The majority of relapses were treated in an outpatient setting, and that the rate of outpatient relapses very sharply declined during pregnancy.

Although the history of developments in Alzheimer has been littered with failures, there remains reason to be hopeful about the future.

The identification of the subtypes allows future studies to target homogeneous subtype samples, resolve inconsistencies, personalize treatment and utilize preventive interventions.

When should aspirin be given in patients with acute ischemic stroke? Plus 4 other questions to test your knowledge of the new guidelines. 

Based on the findings in this early phase, Emerald Health expects to start phase II trials in both MS and scleroderma.

Results presented at the 2018 American Headache Society Annual Scientific Meeting suggested that 20% of participants achieved pain freedom two hours after a single dose of rimegepant, and 48% achieved pain freedom eight hours after that dose, compared to 12% and 32%, respectively, with placebo.

The restless leg syndrome expert spoke about the commonality of both pediatric and adult patients oftentimes misdiagnosed or undiagnosed with RLS.

Proof-of-concept studies using a targeted phenotypic approach to reduce obstructive sleep apnea severity are showing exciting results.

A new analysis of more than a dozen clinical trials has shown no increase in stroke risk for patients with MS, who have shown a higher risk than the general population.

Digital medicine is used to increase access for rural and underserved areas, allowing for the delivery of patient care, patient monitoring and specialist consultations.

Although the differences between groups were not statistically significant, combined findings have shown a risk reduced by close to half.

The identification of 3 key non-anatomical contributors to OSA has unlocked new potential pharmacotherapies, a major advance for the field.

Silberstein spoke about the high prevalence of individuals with migraine in the United States, adding that the major problem in the space today is the lack of resources.